CAMBRIDGE, Mass., Dec. 22, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration), the only biopharmaceutical company focused exclusively on the development and commercialization of new treatment options for people with hemophilia, announced today that the Company has expanded its leadership team with four key hires. Howard Levy, M.D., Ph.D. has joined Inspiration as Chief Medical Officer; Daniel Regan as Chief Commercial Officer; Nikki Hadas as General Counsel; and Karen Tubridy as Vice President and Factor IX Launch Team Leader.
Dr. Levy has over 22 years' experience in the pharmaceutical and medical industries, most recently serving as Chief Medical Officer at Sangart, Inc. Prior to Sangart, he was Associate Vice President, Clinical Research, Medical and Regulatory Affairs, at Novo Nordisk and was responsible for a number of clinical research programs, including the hemostasis platform. Earlier, Dr. Levy was Clinical Research Physician and Medical Director Acute Care in the U.S. Medical Division of Eli Lilly and Company, and Chief of Critical Care Medicine at the University of New Mexico in Albuquerque. Dr. Levy received his Ph.D. and MB BCh from University of Witwatersrand, Johannesburg, South Africa. Dr. Levy serves on the Scientific Advisory Boards of ZZ Biotech and Artisan.
Mr. Regan joins Inspiration from Genzyme Corporation where he held positions of increasing responsibility since 1999, most recently serving as General Manager, Senior Vice President of the U.S. Personalized Genetic Health business unit. At Genzyme, he led multi-functional teams, including sales, marketing and commercialization, across a number of business units, and launched several new products into both large and small markets. In addition to his domestic experience, Mr. Regan worked extensively in Europe, Latin America, and Asian/Pacific markets. Prior to Genzyme, he held sales and marketing positions
|SOURCE Inspiration Biopharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved